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Abstract
Background: The emergence of artemisinin resistance has raised concerns that the most potent antimalarial drug may be
under threat. The currently recommended daily dose of artesunate (AS) is 4 mg/kg, and is administered for 3 days together
with a partner antimalarial drug. This study investigated the impact of different AS doses on clinical and parasitological
responses in malaria patients from an area of known artemisinin resistance in western Cambodia.
Methods: Adult patients with uncomplicated P. falciparum malaria were randomized into one of three 7-day AS
monotherapy regimens: 2, 4 or 6 mg/kg/day (total dose 14, 28 and 42 mg/kg). Clinical, parasitological, pharmacokinetic and
in vitro drug sensitivity data was collected over a 7-day inpatient period and during weekly follow-up to 42 days.
Results: 143 patients were enrolled (n=75, 40 and 28 to receive AS 2, 4 and 6 mg/kg/day respectively). Cure rates were high
in all treatment groups at 42 days despite almost half the patients remaining parasitemic on Day 3. There was no impact of
increasing AS dose on median parasite clearance times, median parasite clearance rates or on the proportion of patients
remaining parasitemic on Day 3. However at the lowest dose used (2 mg/kg/d) patients with parasitemia .10,000/mL had
longer median (IQR) parasite clearance times than those with parasitemia ,10,000/mL (63 (48–75) vs. 84 (66–96) hours,
p,0.0001). 19% of patients in the high-dose arm developed neutropenia (absolute neutrophil count ,1.0610
9/L) by Day 14
and resulted in the arm being halted early.
Conclusion: There is no pharmacodynamic benefit of increasing the daily dose of AS (4mg/kg) currently recommended for
short-course combination treatment of uncomplicated malaria, even in regions with emerging artemisinin resistance, as
long as the partner drug retains high efficacy.
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Introduction
The emergence of artemisinin resistant malaria along the Thai-
Cambodian border has provoked global alarm that the most
valuable and effective antimalarial drug is in danger of being lost,
triggering a campaign to identify and eradicate resistant parasite
strains [1,2] [3]. Despite these concerns the artemisinin resistance
phenotype has been poorly characterized. Decreased parasite
sensitivity to the artemisinin drugs in standardized in vitro tests has
not been reported to date from clinical trials and a molecular
marker for artemisinin resistance remains elusive. The key features
of the phenotype appear to be prolonged parasite clearance times
and slower than expected parasite clearance rates in patients with
adequate plasma drug concentrations [4]. Recently a genetic basis
for this clinical phenotype has been proposed [5]. While cases of
slow parasitological responses can occur sporadically and at low
frequency in any malaria setting, more than 10% of patients in a
given population remaining parasitemic after 3 days of artemisinin
combination therapy (ACT) treatment has been suggested as a
figure to warrant further detailed investigation of parasitological
responses to treatment using AS monotherapy [6], [4].
Experimental seven-day AS monotherapy regimens, although
impractical and inadvisable for routine, unsupervised use, are
valuable research tools and have yielded important scientific
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19283information about potentially resistant parasites without the
confounding influence of the partner drug and without compro-
mising antimalarial treatment efficacy; a daily dose of 4 mg/kg in
a 7-day AS monotherapy regimen was found to have 28-day
efficacy of 93% in a previous study conducted in 2007 in Tasanh,
western Cambodia [7].
This study formed part of the ARC3 (Artemisinin Resistance:
Confirmation, Characterization and planning for Containment)
Project, in which 4 sites (Tasanh and Pailin in western Cambodia,
Wang Pa in northern Thailand and Bandarban in Bangladesh)
were selected to evaluate 7-day artesunate (AS) monotherapy
regimens using harmonized protocols and common endpoints [4].
Data from Pailin and Wang Pa have already been published and
demonstrated for the first time that parasitological outcomes were
significantly different between malaria patients in Pailin and those
in Wang Pa, with slower parasite clearance times in western
Cambodia [8]. Although PCR-adjusted failure rates were higher
in Pailin than Wang Pa the difference was not statistically
significant. The principal objective of this study in Tasanh, an area
of known emerging artemisinin resistance, was to determine the
impact of AS dose on clinical and parasitological responses in
patients with uncomplicated falciparum malaria by employing 3
different AS monotherapy regimens and to test the hypothesis that
higher doses of AS than are currently recommended (.4 mg/kg)
might be effective in eliminating artemisinin resistant strains. An
additional objective was to identify and characterize resistant
malaria parasite populations and describe the clinical phenotype of
drug resistant malaria. Since safety data for this class of drug is
limited a further area of focus was to characterize the safety and
tolerability of higher cumulative doses of AS.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Design
This was a randomized, open-label comparison of 3 regimens of
AS monotherapy given as a single oral dose of 2, 4 or 6 mg/kg/
day (AS2, AS4 and AS6) for 7 days (total doses 14, 28 and 42 mg/
kg) in otherwise healthy adult patients with acute falciparum
malaria. AS2 was selected as the lower limit of what was
considered an effective dose to probe for clinical resistance. The
ratio of enrollment into the 3 groups was 2:1:2 into AS2, AS4 and
AS6 respectively; AS4 was intended to serve as a control and act as
a bridge to an earlier study performed at the same site in 2006/
2007 [7,9].
Study site
Tasanh Health Center is located in Battambang Province in
western Cambodia, close to the Thailand border and due south of
Pailin (Figure 1); this is an area where reports of increasing rates of
ACT failure have emerged over recent years [1]; [8].
Entry criteria
Consecutive patients were recruited into the study if they
fulfilled the following criteria: (1) acute symptomatic P. falciparum
monoinfection as determined by microscopy with a parasite
density of 1000 to 200,000 asexual parasites/mL; (2) fever/history
of fever within 48 hours; (3) age 18–65 years; (4) gave written
informed consent to participate; (5) otherwise healthy outpatients.
Exclusion criteria included the following: (1) pregnancy or
unwillingness to use effective contraception if female and of
child-bearing age; (2) history of intolerance or hypersensitivity to
AS or other artemisinin derivatives; (3) history of any malaria drug
therapy within 30 days; (4) history of other significant illness; (5)
signs or symptoms indicating a requirement for parenteral
antimalarial therapy; (6) signs or symptoms of severe malaria [10].
Randomization and dosing
Randomization was done by an independent statistician using
computer-allocated blocks of 10 and was not stratified; individual
treatment allocations were contained inside consecutively num-
bered sealed envelopes, which were opened sequentially by a study
investigator or clinical research coordinator (CRC) after the
decision to enroll a subject had been made by the study team. AS
doses (using 50 mg tablets, Guilin Pharmaceutical Co. Ltd.,
Guilin, China; quality-controlled and supplied by the World
Health Organization) were calculated individually based on the
patient’s weight at enrollment and the dose rounded up to the
nearest J tablet (12.5 mg). Doses were administered with water
and separated from other concomitant medications wherever
possible. All treatment was directly observed. The full dose was
repeated if vomiting occurred within 30 minutes, and half-dose
given if vomiting occurred within 30–60 minutes. Before the study
commenced 10 randomly selected tablets of study drug were
analyzed in-house for content and weight uniformity according to
standard guidelines [11][12]: the mean AS content was 45.9 mg
(range 41.3–50.2 mg), and dihydroartemisinin (DHA) impurity
was 1.31% (range 1.03–1.62%).
Figure 1. Study location.
doi:10.1371/journal.pone.0019283.g001
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Subjects remained as inpatients for the first 7 days then returned
for follow-up on days 14, 21, 28, 35 and 42. Before initiating AS
therapy blood was drawn to test for in vitro drug sensitivity,
molecular markers of drug resistance and to distinguish later
recrudescence from re-infection by parasite genotyping. Malaria
smears were prepared up to 8 times on Day 0, and then 4 times a
day until 2 consecutive smears were negative for asexual parasites,
then daily until discharge from the ward and then weekly on days
14, 21, 28, 35, and 42, and again if symptoms consistent with
malaria appeared during follow-up. Plasma samples for AS and
DHA concentrations were collected on Day 0 (pre-dose, 15, 30, 60
minutes and 2, 4, 6 and 8 h), and Day 6 (pre-dose, 2, 4 and 6 h)
doses of AS. Additional blood for parasite genotyping and culture
was drawn at the time of treatment failure.
Endpoints
Outcomes at 28 and 42 days, including early treatment failure
(ETF), late treatment failure (LTF) and adequate clinical and
parasitological response (ACPR) were classified according to
standard definitions [13]. The parasite clearance time (PCT100)
was defined as the time from the start of treatment until the first
time the blood smear became negative for asexual parasites and
remained negative at 2 consecutive measurements. PCT90 and
PCT50 were times for the parasitemia to reduce to 90 and 50% of
baseline value. Parasite reduction ratios (PRR) were calculated as
100 minus percentage reduction from baseline level at 24, 48 and
72 hours. The slope of the log10 transformed parasite clearance
curves was used as a measure of parasite clearance rate and
calculated using TableCurve 2D (Systat Software, San Jose,
California). Fever clearance time (FCT) was defined as the time
from baseline until the start of the period in which the tympanic
temperature remained below 38uC for at least 24 hours.
Safety
Because the highest dose arm (AS6) involved a total oral AS
dose of 42 mg/kg, which is higher than other previously published
studies, a number of safety features were built into the study design
(Table 1). These included development of specific individual and
cohort halting rules, the establishment of an independent
chartered Safety Monitoring Committee (SMC), daily assessment
of treatment emergent adverse events during the first 7 days, a
pause for safety review of AS6 after the first 5 patients had
completed treatment, and measurement of complete blood count
(CBC) and alanine aminotransferase (ALT) at baseline, before the
4
th and 7
th AS doses and on Day 14.
Microscopy
Giemsa-stained thick and thin blood smears were examined by
two microscopists blinded to each other’s results and to the
treatment status of the study subject. Parasite densities were
calculated based on a count of parasites per 200 WBCs (thick film)
or per 5000 RBCs (thin film). At least 200 oil immersion fields
were examined on the thick film before a blood smear was
considered negative. The final count was determined by taking the
geometric mean of the two microscopists counts. In case of a
difference in results (positive/negative; species diagnosis) between
the two microscopists, the blood smear was re-examined by a third
microscopist independent of the earlier findings and the third
reading accepted as the final result.
Pharmacokinetics
Whole blood was collected into chilled sodium heparin tubes,
centrifuged immediately, plasma separated and frozen at approx-
imately 220uC or below. Samples were transferred to Bangkok for
analysis by LC-MS [14]. Cmax and Tmax were estimated by
inspection of data. Pharmacokinetic (PK) parameters area under
Table 1. Safety Outcomes and Assessments.
Safety outcome monitored Assessment Individual Halting Rule Cohort Halting Rules
Standard adverse event and serious
adverse event monitoring
Reported from time of informed consent
until final follow-up visit at D42
- N .4 individual halts/arm for the same
event;
N .1 SAE/arm judged probably or
definitely related to study drug
N By discretion of study PI or SMC
N Enrollment pause after first five
subjects in AS6 with resumption
pending SMC review
Treatment Emergent Adverse Event
monitoring daily during artesunate
therapy.
Daily physician clinical assessment
grading severity by CTCAE criteria
-
Myelosuppression CBC with differential at D0, 3, 6 and 14 Neutrophils ,1.0610
9 cells/L;
Hemoglobin ,7.0 mg/dL or
decreased .3.6 mg/dL from
baseline
Neurologic effects Standardized neurological examination
daily for 7 days and at D14
Obtundation; new or worsening
ataxia; .1 seizure
Gastrointestinal or genitourinary Patient report or direct observation
of stools/urine
Visibly bloody stools or urine,
not due to other etiology
Hepatotoxicity Daily physical examination for 7 days;
Plasma ALT at D0, 3, 6 and 14
-
Clinical efficacy Symptom and parasitemia assessments daily
for 7 days; efficacy at D 3, 7, 28 and 42.
Alternate (non artemisinin)
regimen administered for late
treatment failures
.30% clinical failures at D28 in any
treatment arm
Key. D=day after start of treatment; CBC=complete blood count; SMC=Safety Monitoring Committee; ALT=alanine aminotransferase; SAE=serious adverse event;
CTCAE=Common Terminology Criteria for Adverse Events[25].
doi:10.1371/journal.pone.0019283.t001
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calculated for AS and it’s major metabolite dihydroartemisinin
(DHA) by non-compartmental analysis using PK Solutions
Software (Summit Research Services).
Bioassay
Plasma samples from blood collected into sodium heparin were
frozen at 220uC and transported to AFRIMS for analysis.
Determination of antimalarial activity in DHA equivalents against
laboratory strains of P. falciparum (W2) indicating prior use of
antimalarial drugs was performed using a previously described ex
vivo bioassay method [15]; the cut-off value selected was 5 ng/ml
(18 nM).
Clinical labs
CBC samples were collected into EDTA tubes and analyzed
using a Beckman CoulterH AcT5diff analyzer. Plasma ALT
samples were measured using a ReflotronH Plus analyzer (Roche
Diagnostics).
In vitro
Fresh samples, without prior freezing or pre-culturing, were
assayed in the histidine-rich protein 2 (HRP2) drug sensitivity ex
vivo assay for susceptibility to DHA, AS, mefloquine (MQ), quinine
(QN), chloroquine (CQ), and lumefantrine (LUM) [16]. Drug-
coated plates were stored at 4uC and used within 8 weeks of
coating. In order to avoid an innoculum effect, patient specimens
were diluted to a parasitemia between 0.2–0.5% before plating to
enable analysis of IC50 without the confounding effect of baseline
parasitemia. Parasite culture and drug sensitivity assays were
performed as previously described [17]. The CQ-resistant W2 P.
falciparum clone was used as a reference and for quality control of
drug-coated plates.
Parasite genotyping
To distinguish recrudescence from new infection polymor-
phisms in genes encoding the P. falciparum merozoite surface
proteins MSP-1 (National Center for Biotechnology Information
(NCBI) gene ID 813575) and MSP-2 (NCBI gene ID 812660), and
Figure 2. Enrollment, randomization and workflow.
doi:10.1371/journal.pone.0019283.g002
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810501) were compared in individual samples from baseline and
time of failure according to standard methodology [18][19]. The
polymorphic repetitive regions selected were block 2 of MSP-1
(allelic variants from the MAD20, K1 and RO33 families), block 3
of MSP-2 (allelic variants from the FC27 and the 3D7/IC families)
and RII block of GLURP.
Statistical analysis
Sample size estimation assumed a cure rate of 80% in AS2 and
95% in AS6 and was calculated as 60 patients in each of the two
arms with .80% chance of detecting a significant difference in
cure rate by uncorrected Chi-squared test at a two-sided 0.1
significance level. Proportions of patients, both adjusted and non-
adjusted for new infections and for P. vivax parasitemia during
follow-up, were compared between treatment groups using the
Chi-squared and Fishers exact tests. Values of normally distributed
data were expressed as means (95%CI) and non-normally
distributed data as geometric means (95% CI) or medians
(IQR), as appropriate. Means were compared using ANOVA;
otherwise the non-parametric Kruskall-Wallis test was used.
Comparison of failure rates between groups and the proportion
of patients remaining parasitemic over time, were assessed by
modified intention-to-treat (ITT) analysis using Kaplan-Meier
methods and differences between groups compared using the
Logrank test (WHO 2009). Data were analyzed using Stata 10.0
(College Station, Texas) and reported in accordance with
CONSORT methodology [20].
Results
From August 2008 until July 2009 161 patients were screened
and 143 enrolled into the study (Figure 2). Seventy-five, 40 and 28
subjects were randomized to AS2, 4 and 6 respectively. Seven
subjects were subsequently withdrawn; one (in AS6) deteriorated
clinically on Day 1 requiring withdrawal from the study and
transfer to another center for parenteral treatment; an additional 6
(2 in each arm) were either unwilling to continue study
participation or lost to follow-up. Baseline characteristics were
similar in the 3 treatment groups (Table 2). 136 patients completed
7 days of AS monotherapy and were followed to Day 28; 133
completed follow-up to Day 42 (Figure 2, Table 3). Median (range)
weight-adjusted doses were 2 (1.9–2.3) mg/kg, 4 (3.9–4.1) mg/kg
and 6 (5.9–6.1) mg/kg in the 3 groups respectively. Bioassay results
from baseline indicated that only 8/136 (6%) samples had non-
specific pre-existing antimalarial activity above the equivalent of
5 ng/mL DHA.
Eight months after the study started a Cohort Halting Rule was
triggered when a fifth subject in AS6 developed neutropenia;
Table 2. Baseline Characteristics in 143 Patients; intention to treat analysis.
Parameter*
AS2
(n=75)
AS4
(n=40)
AS6
(n=28) Significance‘
Male sex, n (%) 62 (83) 30 (75) 20 (71) 0.16/0.38
Age, y, median (IQR) 25 (20 to 35) 22 (20 to 32) 28 (18 to 38) 0.99/0.47
Weight, kg, mean (95% CI) 53 (51 to 54) 51 (48 to 53) 52 (49 to 54) 0.51/0.42
History of previous malaria episode, n (%) 29 (39) 11 (28) 7 (25) 0.24/0.13
Duration of symptoms, median (IQR) 3 (2 to 4) 3 (2 to 4) 3 (3 to 5) 0.10/0.23
Temperature, uC, mean (SD) 38.0 (37.8 to 38.3) 38.4 (38.0 to 38.7) 38.2 (37.9 to 38.6) 0.36/0.31
Parasitemia, geomean (95%CI) 13,077
(9,872 to 17,324)
18,266
(12,145 to 27,471)
10,923
(6,682 to 17,855)
0.39/0.18
Parasite density group, /mL, n (%)
$1000 and #10,000
.10,000 and #100,000
.100,000
32 (43)
40 (53)
3( 4 )
15 (38)
22 (55)
3( 7 )
15 (54)
11 (39)
2( 7 )
0.37/0.56
White-cell count, 610
23/mm
3, median (IQR) 5.8 (4.6 to 7.5) 6.0 (4.9 to 7.3) 5.4 (4.3 to 6.8) 0.20/0.38
Absolute neutrophil count, 610
23/mm
3, median (IQR) 3.8 (2.7 to 5.1) 4.2 (3.5 to 5.1) 3.8 (3.2 to 5.0) 0.79/0.54
Hemoglobin, g/dl, median (IQR) 12.7 (12.2 to 13.7) 13.3 (12.6 to 14.2) 12.8 (11.1 to 13.7) 0.44/0.21
Hematocrit, median (IQR) 39 (36 to 42) 40 (38 to 43) 37 (33 to 40) 0.012/0.003
Platelet count, 610
23/mm
3, median (IQR) 102,500
(74,250 to 140,000)
107,500
(58,000 to 151,250)
86,000
(66,750 to 148,750)
0.51/0.83
Alanine aminotransferase, U/liter, median (IQR) 21.3 (14.0 to 37.6) 19.5 (13.7 to 30.5) 21.0 (12.0 to 32.6) 0.80/0.76
Bioassay positive, n (%) 4/72 (6) 1/38 (3) 3/26 (12) 0.27/0.30
Presence of Pf gametocytes, n (%) 10 (13) 4 (10) 6 (21) 0.24/0.40
IC50 of fresh cultured parasites, nM,
geometric mean (95%CI)
-A S
- DHA
- Mefloquine
- Quinine
- Chloroquine
- Lumefantrine
4.3 (3.5–5.3)
6.4 (5.0–8.3)
40.8 (30.6–54.4)
115.7 (89.0–150.3)
236.7 (190.2–294.4)
6.7 (5.2–8.7)
5.6 (4.4–7.0)
7.9 (5.8–10.5)
40.1 (26.6–60.5)
106.0 (68.4–164.1)
257.2 (188.1–351.6)
6.1 (4.4–8.4)
7.3 (5.7–9.0)
10.1 (8.1–12.5)
41.6 (27.6–62.5)
160.6 (123.0–209.6)
351.1 (230.0–535.8)
5.8 (3.8–8.8)
0.045/0.22
0.016/0.11
0.94/0.96
0.19/0.41
0.013/0.049
0.51/0.79
Key: Values expressed as median (IQR) unless otherwise specified;
‘X/Y = comparison between AS2 and AS6/comparison between AS2, AS4 and AS6; y = year; Pf = Plasmodium falciparum;
doi:10.1371/journal.pone.0019283.t002
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absolute neutrophil counts (ANC) on Days 6 and 14 in patients in
AS6 and led to permanent suspension of the arm; this finding has
been reported in detail elsewhere [21]. Therefore fewer patients
were recruited into AS6 than AS2. There were no clinically
apparent adverse events associated with the neutropenia. Patients
in AS6 were significantly more likely to meet a halting rule
compared to the other 2 treatment arms (odds ratio 5.9 (95% CI
2.3–15.6, p=0.0003).
Clinical responses
By Day 42 133 patients had met a per protocol efficacy
endpoint: 8 were classified as ETF, 5 as PCR-adjusted LTF, and
120 as ACPR. Per protocol analysis showed no differences in
outcome between treatment groups at Days 28 or 42; all AS
regimens achieved cure in a high percentage of patients (Table 4).
Modified ITT analysis confirmed no difference in cumulative
failure rates between groups (Figure 3). Fever clearance times did
not differ between treatment groups with median (IQR) clearance
times of 14 (5–29), 18 (9–29) and 20 (11–28) hours in AS2, 4 and 6
respectively. Twenty-two patients required treatment with chlo-
roquine for P. vivax infection during the course of the study (10, 5
and 7 in AS2, 4 and 6 respectively); removal of these cases from
outcome analyses did not affect the results (Table 5).
Table 3. Clinical and parasitological responses in 143 patients with acute P.falciparum malaria receiving artesunate monotherapy:
intention to treat analysis.
Variable, median (IQR)
AS2
(n=75)
AS4
(n=40)
AS6
(n=28)
Significance
between groups
¥
Completed 7 doses AS, n (%) 73 (97) 38 (95) 25 (89) 0.12/0.22
Met a halting rule, n (%)
- Neutrophil count ,1.0610
9/L
- Hemoglobin drop .3.6 g/dL
0
0
0
2( 5 )
1
1
5 (18)
5
0
0.001/0.001
Parasite clearance time, h
- Overall
- If parasitemia ,10,000/mm
3
- If parasitemia $10,000 &,100,000/mm
3
- If parasitemia $100,000/mm
3
74 (54 to 90)
63 (48–75)
81 (66–90)
108 (108–120) ‘
78 (66 to 96)
66 (42–78)
85 (66–102)
84 (72–102) ‘ ‘
78 (66 to 96)
72 (66–85)
81 (72–102)
81 (54–108)
0.28/0.38
0.025/0.09
0.52/0.46
0.37/0.19
Time to 50% clearance of parasites, h 7.8 (4.9 to 9.9) 9.3 (7.2 to 12.9) 8.2 (6.3 to 11.9) 0.21/0.11
Time to 90% clearance of parasites, h 19.7 (14.8 to 27.0) 23.5 (17.5 to 30.5) 20.6 (17.5 to 28.8) 0.30/0.26
Parasite-reduction ratio
-A t2 4h
-A t4 8h
7.05 (3.21 to 12.79)
0.93 (0.19 to 2.41)
9.49 (4.06 to 15.85)
0.93 (0.25 to 2.73)
7.65 (3.50 to 17.55)
1.54 (0.33 to 3.77)
0.41/0.60
0.13/0.34
Slope of curve for log10-normalized
parasite clearance
0.040
(0.036 to 0.054)
0.043
(0.036 to 0.055)
0.037
(0.032 to 0.044)
0.11/0.13
Remained parasitemic at 72 h, n (%) 37/75 (49) 18/39 (46) 13/27 (48) 0.55/0.97
Fever clearance, h 14 (5–29) 18 (9–29) 20 (11–28) 0.20/0.26
Recurrent Pf parasitemia* during follow-up, n (%)
- Baseline to day 28
- Day 29 to day 42
- Total
2
1
3 (4)
1
1
2( 5 )
2
0
2 (7) 0.40/0.71
Pv parasitemia during follow-up, n (%)
- Baseline to day 28
- from day 29 to 42
- overall
6
6
12 (17)
2
5
7( 1 9 )
6
1
7 (28) 0.22/0.59
Duration of gametocyte carriage, days, 24 (6–27) 10 (5–17) 17 (14–27) 0.90/0.55
*not PCR-corrected; Kruskall-Wallis test used for comparison of medians;
¥X/Y = comparison between AS2 and AS6/comparison between AS2, AS4 and AS6;
, gametocyte carriage documented in 10, 4 and 6 patients in AS2, 4 and 6 respectively;
‘ p,0.0001 for comparison of parasite clearance times for parasitemia groups within AS2;
‘‘p=0.49 for comparison of parasite clearance times for parasitemia groups within AS4; Pf = Plasmodium falciparum.
doi:10.1371/journal.pone.0019283.t003
Table 4. Outcome: per protocol analyses in patients at 28
(n=136) and 42 (n=133) days; P. vivax cases occurring during
follow-up not removed.
Artesunate
regimen
Outcome parameter*
n (% of total)
Total
number
ETF
LTF*
(PCR-adjusted) ACPR
AS2
28 days
42 days
5( 7 )
5( 7 )
1( 1 )
2( 3 )
66 (92)
64 (90)
72
71
AS4
28 days
42 days
1( 3 )
1( 3 )
1( 3 )
1( 3 )
36 (94)
34 (94)
38
36
AS6
28 days
42 days
2( 8 )
2( 8 )
2( 8 )
2( 8 )
22 (84)
22 (84)
26
26
Key. Fishers exact test shows no differences between treatment groups at 28 or
42 days (p=0.41 and p=0.65 respectively); ETF = early treatment failure; LTF =
PCR-corrected late treatment failure; ACPR = adequate clinical and
parasitological response [13];
*LTFs were further classified as follows: AS2: 16LCF at 28d and 16LCF at 35d;
AS4: 1 6LPF at 28d; AS6: 1 6LCF at 24d and 1 6LPF at 28d.
doi:10.1371/journal.pone.0019283.t004
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was classified as ETF after a clinical deterioration on Day 1,
which required transfer to another center for continued care.
The remaining 7 cases had fever plus parasitemia on Day 3,
though all were much improved clinically from presentation
(Table 6). Six were allowed to continue their randomized AS
regimen and all cleared parasites and fever within the following
1–2 days. One of these 6 patients subsequently had reappearance
of mixed P. falciparum/P. vivax parasites on Day 35, but PCR
genotyping indicated a new P. falciparum infection; the other 5
remained parasite-free to Day 42. The 7
th patient received
rescue treatment with quinine-tetracycline on Day 4 and
recovered uneventfully.
Late treatment failures. P. falciparum parasites reappeared
during 42 days of follow-up in 8 cases, of whom 5 were confirmed
as recrudescence by PCR genotyping (Table 6). A 9
th patient
returned with P. falciparum parasitemia on Day 58, 16 days outside
the follow-up period; PCR genotyping confirmed recrudescence;
notably this patient had received CQ 25 mg/kg for P. vivax
infection detected on Day 21, which may have delayed the P.
falciparum recrudescence. PCR genotyping of MSP-1, MSP-2 and
GLURP in baseline samples indicated that 7 of these 9 patients
had polyclonal infections.
Parasitological responses
ITT analysis showed no differences between groups in median
PCT100, PCT90, or PCT50, or in parasite reduction ratios at 24, 48
or 72 hours (Table 3, Figure 4). However, within AS2 patients
with parasitemia .10,000/mL had significantly longer median
(IQR) PCT100 than those with baseline parasitemia ,10,000/mL
(63 (48–75) vs. 84 (66–96) hours, p,0.0001); there was a similar
but smaller effect seen in AS4 (p=0.049), but not in AS6
(p=0.65). This dose-effect was not seen for PCT90 or PCT50.
Comparison of the slope of the log10 transformed parasite
clearance curves showed no significant difference between
treatment groups, and multiple regression analysis using slope as
the dependent variable showed no significant association with
parasitemia, history of previous malaria, IC50 DHA or treatment
allocation. However comparison of the parasite clearance slopes
between patients with a subsequent per protocol failure and those
cured at 42 days showed a small but significant difference (0.037
(0.032–0.039 vs 0.041 (0.034–0.054, p=0.032). Seventy-two hours
after AS treatment commenced almost 50% of patients still had
asexual parasites on a peripheral blood smear (49%, 46% and
48% in AS2, 4 and 6 respectively).
Comparison of parasitological responses between recrudescent
subjects and those successfully cured at 42 days showed
significant differences in PCT100 (Table 7). However the median
PCT100 for cured subjects was still 72 hours, which is similar to
the published value from Pailin (Table 8). Only 24 (17%) patients
had rapid PCT100 (#48 h) (Table 9). Compared to the 29
patients with PCT100 $96 h the rapid clearance group had
significantly lower median baseline parasitemia and fewer per
protocol failures (p,0.001 and p=0.004 respectively); moreover
the median slope of the log10 transformed parasite clearance
curves was steeper in these rapid clearers than in patients with
PCT100 $96 hours (0.03 vs 0.08, p=0.0001). Plasma concen-
trations of AS and DHA could not explain the difference in
clearance between these two groups. Compared to patients with
PCT100 .48 h patients with PCT100 #48 h were more likely to
have a history of previous malaria (58% vs 28%, p=0.006). For
patients remaining parasitemic at Day 3 or with PCT100 $96 h
the odds ratios (95% CI) of per protocol failure were 5.9 (1.2–
29.3) and 4.6 (1.3–16.1) respectively. For patients remaining
parasitemic at Day 3 or with PCT100 $96 h the odds ratios (95%
CI) of PCR-adjusted recrudescence within 42 days were 4.4 (0.5–
41.8) and 16.9 (1.6–176.5) respectively.
Significantly more patients remained parasitemic at 72 hours in
the second compared to the first 6 months of the study (58 vs 39%,
p=0.016), despite an even distribution of treatment allocation in
each period. Patients in the second half of the study were less likely
to give a history of a diagnosis of malaria within the previous 12
months (55 vs 77% p=0.005). They also had a lower occurrence
of gametocytes on a baseline peripheral blood smear (7 vs 22%,
p=0.009) and a reduced P. vivax relapse rate during follow-up (14
vs 25%, p=0.08).
Pharmacokinetics
Pharmacokinetic (PK) profiles were obtained following the first
AS dose in all 143 subjects and also around the final dose in the
136 subjects completing 7 days of monotherapy. As expected
median Cmax and AUC0-8h for AS and DHA increased with AS
dose but there was wide variation in individual plasma levels. PK
values (Cmax and AUC0-8h for AS and DHA) for PCR-confirmed
recrudescence cases were all above the 25
th percentile of the
median of the respective parameters compared to the 64 subjects
cured with AS 2 mg/kg/day. In aggregate the 8 patients classified
as ETF had comparable drug levels to those cured (Table 7);
Table 5. Outcome: per protocol analysis in 109 patients at 42
days; P. vivax relapse cases censored from analysis.
Artesunate
regimen
Outcome parameter*
n (% of total)
Total
number
ETF
LTF
(PCR-adjusted) ACPR
AS2
42 days 5 (8) 2 (3) 53 (88) 60
AS4
42 days 1 (3) 1 (3) 27 (90) 30
AS6
42 days 2 (11) 2 (11) 15 (79) 19
Key. Fishers exact test shows no differences between treatment groups at 42
days (p=0.57); ETF = early treatment failure; LTF = PCR-corrected late
treatment failure; ACPR = adequate clinical and parasitological response [13].
doi:10.1371/journal.pone.0019283.t005
Figure 3. Modified intention-to-treat analysis: outcome mea-
sured to 42 days.
doi:10.1371/journal.pone.0019283.g003
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19283however, one case had low AUC and another low Cmax for both
AS and DHA. Comparing PK parameters from this study to
recently published data (Table 10), half-life and Tmax were
comparable but overall drug exposure based on Cmax and AUC
expressed in the same units was higher in Tasanh.
In vitro drug-sensitivity testing
IC50 data are shown in Figure 5. Sigmoidal dose response
curves were obtained from DHA and AS coated HRP2 ELISA
plates in 131 of 143 (92%) subjects; 67/75 in AS2; 39/40 in AS4,
and 25/28 in AS6. Median (IQR) IC50 values for DHA were 8.19
(IQR 5.13–14.0) nM and for AS were 5.66 (3.57–7.81) nM, more
than double the values measured at the same site using the same
methodology 3 years previously
1. Individual IC50 values for DHA
and AS did not correlate well with most parasitological
parameters, and did not differentiate between cured and
recrudescent patients (Table 7). In contrast, the median (IQR)
DHA IC50 for patients remaining parasitemic at 72 hours was 9.60
(6.82–14.7) nM, significantly higher than the median IC50 of 6.26
(4.22–13.4) nM for subjects clearing parasites within 72 hours
(p=0.013). There was no significant difference observed between
AS IC50 for patients who were and were not parasitemic at
72 hours (5.98 vs. 5.38 nM, p=0.067).
Discussion
This is the largest reported clinical trial to characterize clinical
and parasitological responses to AS monotherapy in a region of
artemisinin resistant malaria and evaluate a public health strategy
to overcome these slow responses. Although impractical and
inadvisable for routine, unsupervised use, AS monotherapy
regimens are important research tools and allow detailed analysis
of the dose response to AS without the confounding influence of a
partner drug. Despite high treatment efficacy almost 50% of
patients in this study population remained parasitemic 72 h after
commencing AS, suggesting an alarming trend towards artemisi-
nin resistance in the parasite population [4,6]. Moreover PCTs
were similar to those reported from Pailin, previously the best
characterized area of emerging resistance, despite a 4-fold lower
median parasitemia in Tasanh [8].
This study was designed to investigate whether resistant P.
falciparum strains may require higher doses of AS to achieve the
same clinical and pharmacodynamic effects as fully sensitive
strains. However, because per protocol cure rates in Tasanh were
Figure 4. Modified intention-to-treat analysis: proportion of
patients remaining parasitemic by treatment arm.
doi:10.1371/journal.pone.0019283.g004
Table 7. Parasitological, clinical and in vitro responses in early treatment failures, recrudescent and cured patients; data expressed
as median (IQR) unless otherwise stated.
Parasitological and clinical
responses
Cured at 42 days
(n=120)
Early treatment failure
(n=8)
Comparison of
cured and ETF‘
Recrudescent within 42d
(n=5)
Comparison of
cured and LTF‘
Baseline parasitemia, /mL,
geometric mean (95%CI)
11,406
(4,760–30,736)
38,981
(21,398–48,294)
0.07 22,863
(8,689–55,513)
0.34
Cmax DHA Day 0, nM 917
(498–1681)
1068
(683–2304)
0.45 1440
(396–1642)
0.82
AUC0-8 DHA Day 0, h.nM 2283
(1212–4291)
2306
(1537–6701)
0.60 2457
(1893–3067)
0.85
PCT50, h 8 (5–11) 11 (5–18) 0.32 11 (9–12) 0.08
PCT90, h 20 (15–28) 35 (15–43) 0.12 35 (25–39) 0.02
PCT100, h 73 (60–90) 90 (84–96) 0.02 96 (96–108) 0.006
PRR24 7.1 (3.4–13.2) 21.4 (9.1–36.6) 0.01 18.9 (12.8–21.7) 0.03
PRR48 0.94 (0.23–2.61) 2.41 (1.22–5.57) 0.02 3.34 (1.87–3.77) 0.02
Slope of curve for log10-
normalized parasite clearance
0.041
(0.034–0.054)
0.037
(0.030–0.038)
0.09 0.037
(0.033–0.039)
0.18
FCT, h 15 (7–28) 81 (13–84) 0.005 27 (19–27) 0.15
IC50 DHA, nM
Baseline
Recrudescent
8.0 (5.0–13.5)
-
10.6 (4.5–14.0)
-
0.70 8.9 (5.5–16.0)
7.0 (5.1–9.2)
0.49
IC50 AS, nM
Baseline
Recrudescent
5.4 (3.4–7.7)
-
5.8 (4.1–7.2)
-
0.61 6.9 (4.9–10.7)
4.6 (4.5–7.5)
0.13
Cured refers to patients not meeting a parasitological endpoint and completing 42 days follow-up; recrudescent refers to PCR-corrected late treatment failures
occurring during the 42 day follow-up; ‘Comparison of non-parametric data using Kruskall-Wallis test.
doi:10.1371/journal.pone.0019283.t007
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19283high in all dosing groups, a finding in keeping with some other
recent studies of AS monotherapy, we did not demonstrate
improved 42-day efficacy using high-dose treatment. Even if the
high-dose arm had recruited its planned allocation of subjects we
would not have been able to demonstrate a dose-dependent effect
between groups in terms of clinical outcome. This contrasts with
the 30% recrudescence rate and prolonged fever clearance seen
in Pailin; there, the high failure rate might in part be explained
by the much higher median parasitemia at baseline (due to
differing entry criteria), and lower apparent drug concentrations
(Table 10) as well as a smaller sample size. Even the higher
parasitemia patients in Tasanh did not have this clinical failure
rate. Interestingly, the proportion of patients in Tasanh
remaining parasitemic at 72 hours noticeably increased as the
study progressed, which could indicate the emergence of more
resistant clones in the parasite population [5], as well as reflect
the changing epidemiology of malaria in western Cambodia as
evidenced by fewer patients reporting a history of malaria
diagnosed within the preceding 12 months. Median parasite
clearance times in Tasanh were still considerably longer than
those reported in Wang Pa in northern Thailand, despite lower
median parasitemias in Tasanh, demonstrating that the phenom-
enon of slow parasite clearance is not simply dictated by the
baseline parasitemia.
We did not demonstrate any improvement in pharmacody-
namic responses when higher doses of AS were given. Within AS2
however we did observe that parasitemia .10,000/mLi s
associated with significantly prolonged median PCT100. This is
likely to be explained by plasma drug concentrations being much
closer to the MIC than when higher AS doses were administered.
Interestingly this dose effect was not observed for PCT90 or
PCT50; one explanation is that the more resistant clone(s) in a
polyclonal infection may require more parasite lifecycles before
complete killing occurs, and that PCT50 and PCT90 values reflect
killing of the more sensitive clones. Only 17% patients in this study
were rapid parasite clearers (PCT100 #48 h); these patients had a
significantly lower median parasitemia and a higher reported
history of previous malaria episodes indicating some degree of
prior immunity; none failed treatment during 42d. The influence
of both parasitemia and immunity on parasite clearance times has
been well described previously [22]. The only significant dose-
dependent adverse effect that was seen was the finding of
myelotoxicity in AS6 which we have reported in detail elsewhere
[21]. Clearly, dose escalation of the artemisinin component of an
Table 8. Comparison of clinical and parasitological outcomes with other published data (Dondorp, 2009).
Tasanh
All
Tasanh
Parasites $10
4/mL 1
Pailin
Parasites $10
4/mL
Wang Pa
Parasites $10
4/mL
Outcomes
AS2
(n=75)
AS4
(n=40)
AS2
(n=43)
AS4
(n=25)
AS2
(n=20)
AS4*
(n=20)
AS2
(n=20)
AS4*
(n=20)
PCT100 (h), overall,
median (IQR)
if P0 , 10
4/mL
if P0 $10
4and ,10
5/mL
if P0 $10
5/mL
74
(54–90)
63
(48–75)
81
(66–90)
108
(108–120)
78
(66–96)
66
(42–78)
85
(66–102)
84
(72–102)
84
(66–96)
-
81
(66–90)
108
(108–120)
84
(72–102)
-
85
(66–102)
84
(72–102)
85.9
(54, 96)
-
72
(48–96)
90
(84–96)
72
(60, 96)
-
66
(60–84)
96
(90–108)
54.1
(42, 72)
-
54
(42–72)
54
(54–72)
48
(30.1, 54)
-
48
(30–54)
60‘
(2)
PCT50,h ,
median (range)
8
(0.2–31)
9
(1.9–22)
8
(1–18)
10
(2–16)
11
(1–25)
9
(1–22)
4
(1–24)
3
(1–16)
PCT90,h ,
median (range)
20
(2.2–58.6)
24
(4–50)
20
(10–43)
24
(10–50)
23
(8–39)
21
(11–44)
12
(3–40)
11
(3–27)
PRR24,
median (range)
7
(0–170)
9
(0–41)
8
(0–31)
10
(0–24)
18.7
(0.3–97.2)
13.5
(0.9–67.6)
1.1
(0.0–54.1)
0.03
(0.0–15.0)
PRR48,
median (range)
0.9
(0–19.1)
0.9
(0–7.2)
0.9
(0–7.5)
0.7
(0–7.0)
0.5
(0.0–11.4)
0.6
(0.0–10.0)
0.0
(0.0–3.8)
0.0
(0.0–0.5)
Parasitemic at 72h, n (%) 37
(49)
18
(46)
29
(67)
14
(56)
22/40
(55)¥
3/40
(8)¥
ETF, n (%) 5 (7) 1 (3) 4 (11) 1 (4) 3/40 (8)¥ 0 (0) 0 (0)
Recrudescence,
n( % )
2 (3) 1 (2) 1 (2) 1 (4) 6 (30) 1 (5) 2 (10) 1 (5)
Reinfection,
n( % )
1 1 (2) 1 (2) 1 (4) 1 (5) 0 (0) 8 (40) 4 (20)
PV or mixed,
n( % )
11/1 (15/1) 7/0 (19/0) 6/1 (14/2) 1/0 (4/0) 5/1 (30/5) 7/0 (35/0) 1/3 (20/15) 0/2 (10/10)
FCT, d,
median (IQR)
0.6
(0.2, 1.2)
0.8
(0.4, 1.2)
0.7
(0.3, 1.2)
1.0
(0.4, 1.3)
50% had
FCT .7d
3
(2, -)
2
(1, 2)
2
(1, 2)
Gam. clearance, d,
median (IQR)
24
(6–27)
10
(5–17)
17
(4–27)
-1 0
(7–19)
18
(6–23)
19
(7–19)
13
(1–19)
1Tasanh patients with baseline parasitemia .10,000 parasites m/L;
*Pailin and Wang Pa AS4 groups received AS 4 mg/kg 63 days followed by mefloquine 15 and 10 mg/kg on days 3 and 4;
‘ n=1 therefore IQR not possible;
¥ Paper does not differentiate this value by treatment arm; P0 = baseline parasitemia; Gam = gametocyte; Data are expressed in the units used in the Dondorp paper [8].
doi:10.1371/journal.pone.0019283.t008
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effects of the drug on the neutrophil in malaria patients have been
better defined, particularly if other factors known to be
myelosuppressive, including partner antimalarial drugs, are
present.
The lack of a clear difference in median IC50 for DHA and
AS between failures and cures was surprising, but is in keeping
with previous reports from this region [8]. One explanation is
that, since some P. falciparum infections are known to be
polyclonal, the wild-type, non-artemisinin resistant clone may
have a selective advantage in the environment over the
artemisinin resistant clone. Although the degree of polyclonality
of malaria infections in Tasanh has not yet been demonstrated,
PCR genotyping in the subset of patients from this study with
reappearance of P. falciparum parasites indicated that 7 of 9
(78%) had polyclonal infections at baseline. Moreover analysis
of both Thai and African isolates by Druihle et al revealed 33
and 34 clones respectively in primary specimens [23]; although
many of these isolated clones were related genetically, they
exhibited high degrees of diversity including their in vitro
responses to antimalarial drugs. Our in vitro technique involves
culture of fresh isolates in the field (‘‘ex-vivo’’) to mitigate losing
clones, perhaps artemisinin resistant clones, which may not
survive cryopreservation. Even so, this technique still does not
allow easy differentiation of small clonal populations from
within a polyclonal primary sample. The finding of lower
median IC50 DHA and AS in recrudescent isolates at baseline
might be explained by the very low parasitemias seen at
Table 9. Comparison of clinical, parasitological and laboratory parameters of patients with rapid or slow parasite clearance.
Parameters
Median (IQR)
Long PCT ($96 h)
n=29
Rapid PCT (#48 h)
n=24
Comparison between
groups
Age, y 24 (20–31) 25 (19–34) 1.0
Weight, Kg 52 (50–55) 52 (46–57) 0.79
Male sex, n (%) 24 (83) 21 (88) p=0.47
History of previous malaria, n (%)
1 episode
2 episodes
3 episodes
.3 episodes
10 (34)
8
1
1
0
14 (58)*
6
5
2
1
p=0.07
History of artemisinin use for a previous malaria episode, n (%) 1 (3) 5 (21)** p=0.06
History of mefloquine use for a previous malaria episode, n (%) 2 (7) 3 (13) p=0.41
Positive bioassay at baseline, n (%) 0/29 (0) 1/23 (4) P=0.44
Parasitemia, (/mL), geo.mean (95% CI)
, 10,000/mL, n (%)
$10,000 and ,100,000/mL, n (%)
$100,000/mL, n (%)
31,884 (21,209–47,930)
4/62 (6)
20/73 (27)
5/8 (63)
D
8,158 (4,717–14,110)
15/62 (24)
9/73 (12)
0/8 (0)
DD
p=0.0005
Gametocytes at baseline, n (% positive) 3 (10) 1 (3) p=0.56
AS regimen, n (% of group)
AS2
AS4
AS6
12 (16)
10 (29)
7( 2 5 )
15 (20)
6 (15)
3 (11)
p=0.33
PCT100, h 102 (96–108) 36 (30–42) p=0.0001
PCT50, h 10.7 (9.5–15.1) 5.9 (3.6–8.0) p=0.0001
PCT90, h 31.2 (24.4–37.2) 13.6 (10.1–16.9) p=0.0001
PRR24 14.3 (10.5–21.7) 1.2 (0.1–3.2) p=0.0001
Slope of curve for log10-normalized parasite clearance 0.035 (0.031–0.037) 0.084 (0.057–0.107) p=0.0001
IC50 DHA, geometric mean (95% CI) 9.0 (7.4–11.0) 6.5 (4.6–9.1) p=0.09
IC50 AS, geometric mean (95% CI) 6.2 (5.2–7.4) 4.0 (2.9–5.5) p=0.04
IC50 Mefloquine, geometric mean (95% CI) 37.4 (23.5–59.5) 44.2 (28.2–69.3) p=0.72
IC50 Chloroquine, geometric mean (95% CI) 324 (247–425) 290 (228–370) p=0.51
Outcome
ETF, n (%)
Recrudescence, n (%)
Any per protocol failure, n (%)
2
4
6
0
0
0
p=0.33
p=0.09
p=0.02
Vivax infection, n (%) 5/27 (17) 6/23 (26) p=0.26
FCT, h, 18.8 (10.5–28.7) 14.2 (0.4–25.6) p=0.12
Cmax DHA, nM, 1286 (766–2085) 829 (400–1471) p=0.19
AUC0-8* DHA, h.nM, 2457 (2007–4760) 1961 (1259–3081) p=0.26
DPatients with prolonged PCT more likely to have higher parasitemia than rest of study patients, p,0.0001;
DDp=0.086 for rapid PCT patients compared to rest of study patients;
*p=0.005 comparing rapid PCT group with rest of study patients; **p=0.033 for rapid PCT patients compared to rest of study patients.
doi:10.1371/journal.pone.0019283.t009
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strong relationship between parasite count and HRP2 level; in
high parasitemias this is corrected for by dilution of the fresh
sample prior to plating, but the converse is not possible with
current methodologies. Additional work is needed to standard-
ize in vitro methodologies as well as optimize strategies for
isolating resistant clones from polyclonal infections.
A crucial observation was that 5 of 6 cases meeting ETF
criteria of fever and parasitemia on Day 3 who continued AS
monotherapy went on to clear parasites and remained cured to
Day 42 without a requirement for rescue treatment; the 6
th
patient had a mixed infection on Day 35 but the P. falciparum
component was a new infection. This indicates that prolonged
courses of AS were still effective in curing the malaria infection
despite slow clinical and parasitological responses. Two of these
ETF cases had sub-optimal plasma drug concentrations despite
receiving weight-based dosing and directly observed therapy. The
huge variability seen in individual pharmacokinetic profiles in
malaria patients, even in the highly controlled environment of a
clinical research trial, emphasizes the importance of controlling
unregulated use of poor quality drugs, which likely plays a
significant role in inducing resistance in low transmission settings
[24].
In summary this study demonstrates that the parasitological
response to antimalarial therapy is a complex interaction of factors
including parasitemia, immune status, plasma drug concentrations
and innate parasite resistance to the antimalarial drug. Increased
doses of AS did not impact on clinical or pharmacodynamic
outcomes in this setting of emerging artemisinin resistant malaria
and were toxic at the highest cumulative dose evaluated. Since
completion of this clinical trial, Tasanh has been at the center of a
high profile containment program; only time will tell if these efforts
have been successful or whether artemisinin resistant clones have
already spread. Artemisinin resistance remains a significant threat
to the malaria-endemic world and this study highlights that simple
dose escalation is not a viable strategy to overcome it. Continued
coordinated public health strategies are necessary to keep this
threat at bay.
Table 10. Comparison of baseline and pharmacokinetic parameters with other published data (Dondorp, 2009).
Tasanh
All
Tasanh
Parasites $10
4/mL 1
Pailin
Parasites $10
4/mL
Wang Pa
Parasites $10
4/mL
Baseline
characteristics
AS2
(n=75)
AS4
(n=40)
AS2
(n=43)
AS4
(n=25)
AS2
(n=20)
AS4*
(n=20)
AS2
(n=20)
AS4*
(n=20)
Age, y,
mean (95% CI)
28.9
(26.4, 31.3)
27.0
(23.4, 30.5)
28.7
(25.4, 32.0)
25.6
(21.3, 29.9)
26.6
(20.5, 32.7)
21.6
(16.4, 26.9)
31.4
(27.8, 34.9)
29.7
(25.5, 33.9)
Weight, kg,
median (IQR)
53.0
(47.5, 56.3)
50.5
(47.4, 54.9)
52.7
(47.7, 55.7)
51.5
(47.8, 55.1)
46.5
(20.5, 60)
47.0
(21, 62)
55
(35, 66)
51
(39, 59)
Male sex, n (%) 62 (83) 30 (75) 36 (84) 19 (76) 15 (75) 16 (80) 19 (95) 20 (100)
Hemoglobin, g/dL,
mean (95% CI)
13.0
(12.6, 13.3)
13.2
(12.6, 13.8)
12.4
(12.1, 14.0)
13.7
(12.7, 14.8)
11.8
(10.8, 12.8)
12.0
(10.9, 13.1)
12.5
(11.7, 13.3)
12.4
(11.6, 13.3)
Platelets, 610
3/mL,
median (IQR)
103
(74–140)
108
(58–151)
96
(70–152)
84
(48–127)
82
(17–357)
113.5
(40–383)
120.5
(47–410)
104
(29–357)
Parasitemia, /mL,
geometric mean
(95% CI)
13077
(9872, 17324)
18266
(12145, 27471)
31174
(24934, 38977)
42258
(31702, 56327)
64166
(39155, 105153)
65299
(40813, 104474)
37214,
(26391, 52477)
22746
(13888,
37252)
Gametocytes,
n (% positive)
10 (13) 4 (10) 6 (14) 0 (0) 5 (25) 6 (30) 6 (30) 5 (25)
Pharmacokinetics
Cmax AS, nM,
median (range)
219
(29–2500)
578
(198–3141)
196
(49–2500)
556
(197–3141)
248
(28–897)
290
(34–1620)
186
(35–544)
219
(50–1560)
Tmax AS, h,
median (range)
0.5
(0.25–4.0)
0.5
(0.25–2.0
0.5
(0.25–4.0)
0.5
(0.25–1.0)
0.5
(0.25–2.0)
1.0
(0.25–2.0)
0.38
(0.25–0.98)
0.5
0.25–3.0)
AUC** AS, h.nM,
median (range)
219
(60–1140)
716
(336–3708)
218
(56–1141)
718
(386–3707)
159
(53–342)
310
(122–738)
139
(70–252)
264
(93–553)
T1/2 AS, h,
median (range)
0.46
(0.12–2.7)
0.45
(0.17–5.4)
0.46
(0.12–2.1)
0.48
(0.17–5.4)
0.29
(0.13–1.42)
0.33
(0.18–1.05)
0.37
(0.14–3.00)
0.55
(0.13–1.13)
Cmax DHA, nM,
median (range)
1908
(507–5801)
5560
(1697–29792)
1998
(505–5804)
6193
(1696–11764)
737
(142–2780)
1460
(771–4680)
937
(162–1766)
1300
(511–3500)
Tmax DHA, h,
median (range)
1.0
(0.5–6.0)
1.0
(0.5–4.0)
1.0
(0.5–6.0)
1.0
(0.5–4.0)
1.0
(0.5–4.0)
1.5
(0.42–3.0)
1.0
(0.48–2.98)
1.01
(0.48–3.0)
AUC** DHA, h.nM
median (range)
4556
(827–11975)
12944
(5493–73370)
4529
(826–11975)
13125
(5491–73370)
1270
(490–4030)
3780
(1710–5200)
1430
(604–2900)
3240
(1480–6220)
T1/2 DHA, h
median (range)
0.8
(0.3–3.2)
0.9
(0.4–3.5)
0.7
(0.4–3.2)
0.9
(0.4–3.5)
0.8
(0.5–1.4)
0.7
(0.5–1.5)
0.7
(0.4–1.3)
0.8
(0.5–1.4)
1 Tasanh patients with baseline parasitemia .10,000 parasites m/L;
*Pailin and Wang Pa AS4 groups received AS 4 mg/kg 63 days followed by mefloquine 15 and 10 mg/kg on days 3 and 4;
**AUC is 0–8 h for Tasanh and 0–24 hours for Pailin/Wang Pa; P0 = baseline parasitemia; Gam = gametocyte; Data are expressed in the units used in the Dondorp
paper [8].
doi:10.1371/journal.pone.0019283.t010
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